Proposed changes to ABPI Code of practice could hurt smaller firms, warns EMIG - update
This article was originally published in Scrip
Executive Summary
Proposed changes to the ABPI (Association of the British Pharmaceutical Industry) code of practice, now out for consultation, could help improve transparency in the pharmaceutical industry. But plans to limit branded giveaways to healthcare professionals could disproportionately hurt smaller firms, making the code "unfit for purpose", warns the Ethical Medicines Industry Group, EMIG.
You may also be interested in...
Real World Data Failed To Impress Kaftrio’s European Reviewers
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Australian Industry Maps Path To Better Use Of Real World Evidence
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
Need a specific report? 1000+ reports available
Buy Reports